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ABSTRACT Carbapenem-resistant (CR) sequence type 258 (ST258) Klebsiella pneu-
moniae has become an urgent health care threat, causing an increasing number of high-
mortality infections. Its resistance to numerous antibiotics and threat to immunocompro-
mised patients necessitate finding new therapies to combat these infections. Previous
successes in the laboratory, as well as the conservation of capsular polysaccharide (CPS)
among the members of the ST258 clone, suggest that monoclonal antibody (MAb) ther-
apy targeting the outer polysaccharide capsule of K. pneumoniae could serve as a valu-
able treatment alternative for afflicted patients. Here, we isolated several IgG antibodies
from mice inoculated with a mixture of CR K. pneumoniae CPS conjugated to anthrax
protective antigen. Two of these MAbs, 17H12 and 8F12, bind whole and oligosaccha-
ride epitopes of the CPS of clade 2 ST258 CR K. pneumoniae, which is responsible for the
most virulent CR K. pneumoniae infections in the United States. These antibodies were
shown to agglutinate all clade 2 strains and were also shown to promote extracellular
processes killing these bacteria, including biofilm inhibition, complement deposition, and
deployment of neutrophil extracellular traps. Additionally, they promoted opsonophago-
cytosis and intracellular killing of CR K. pneumoniae by human-derived neutrophils and
cultured murine macrophages. Finally, when mice were intratracheally infected with pre-
opsonized clade 2 CR K. pneumoniae, these MAbs reduced bacterial dissemination to or-
gans. Our data suggest that broadly reactive anticapsular antibodies and vaccines
against clade 2 ST258 CR K. pneumoniae are possible. Such MAbs and vaccines would
benefit those susceptible populations at risk of infection with this group of multidrug-
resistant bacteria.
IMPORTANCE Carbapenem-resistant Klebsiella pneumoniae is an enteric bacterium
that has been responsible for an increasing number of deadly outbreaks and hospital-
acquired infections. The pathogen’s resistance to numerous antibiotics, including
new drugs, leaves few therapeutic options available for infected patients, who often
are too sick to fight the infection themselves. Immunotherapy utilizing monoclonal
antibodies has been successful in other medical fields, and antibodies targeting the
outer polysaccharide capsule of these bacteria could be a valuable treatment alter-
native. This study presents two anticapsular antibodies, 17H12 and 8F12, that were
found to be protective against the most virulent carbapenem-resistant K. pneu-
moniae clinical strains. These antibodies are shown to promote the killing of these
strains through several extracellular and intracellular processes and prevent the
spread of infection in mice from the lungs to distal organs. Thus, they could ulti-
mately treat or protect patients infected or at risk of infection by this multidrug-
resistant bacterium.
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The Gram-negative bacterium Klebsiella pneumoniae presents a dire health careproblem. Already a common nosocomial pathogen that causes chronic urinary tract
infections, pneumonias, and sepsis, the pathogen has become even more successful in
the last decade because of emerging multidrug resistance to antibiotics. Infections with
these strains are associated with mortality rates of 50%, particularly in hospitalized
patients with comorbidities (1–3). Additionally, recent reports of carbapenem-resistant
(CR) K. pneumoniae strains that have acquired a hypervirulent phenotype indicate that
these strains could soon also cause disease in healthy people in the community (4).
With reports of already emerging resistance to ceftazidime-avibactam (5) and limited
development of other Gram-negative antibiotics (6), novel strategies to combat CR K.
pneumoniae are urgently needed.
Though still an emerging field, treatment of infections with antibodies has shown
some success, and to date, four such monoclonal antibodies (MAbs) are FDA licensed
(7). Numerous laboratories, including ours, have demonstrated protective efficacy of
anti-infective antibodies in murine models (8–12). As MAbs target specific pathogens,
they are less likely to disturb the microbiome. Yet the specificity of antibodies also
drives antigenic variability of pathogens and can make finding appropriate targets
the most difficult hurdle in MAb development. While carbohydrate antigens, such as
the antiphagocytic capsular polysaccharide (CPS), are the most accessible targets on
the surface of K. pneumoniae and other members of the family Enterobacteriaceae, their
variety has discouraged attempts to use them in immunotherapy.
In the United States, the sequence type 258 (ST258) clone comprises 80% of the CR
K. pneumoniae strains and has been subcategorized into two evolutionary groups,
termed clades 1 and 2 (13). Infection with clade 2 strains, which encompasses about
50% of the United States ST258 strains (1) and up to 88% of the ST258 strains in other
countries, has been associated with a higher mortality rate than infection with clade 1
strains (1, 14–16). Notably, the 2009 outbreak at the National Institutes of Health Clinical
Center in Bethesda, which resulted in nine deaths, was also caused by a clade 2 strain
(17). Genetic differentiation of these two clades results from DNA recombination events
in an ~215-kb genomic region that includes the gene cluster involved in CPS biosyn-
thesis (13). Molecular typing of the wzi gene alleles, which has replaced serological
typing, indicates higher conservation of CPS in clade 2 strains than in clade 1 strains, as
nearly all clade 2 strains possess the wzi-154 allele (18). We previously developed an IgM
antibody, 1C9, that was shown to agglutinate 16/16 clade 2 strains tested and 1/7 clade
1 strains. However, as an IgM isotype, its affinity was too low and attempts to switch the
isotype of this antibody failed (18).
In this study, we developed novel IgG antibodies by immunizing mice with protein-
conjugated CPS, which improved the probability of generating IgG-producing hybrid-
omas. We now present data showing that IgG3s 17H12 and 8F12, which bind to clade
2 CPS, exhibit broad opsonophagocytic killing efficacy against clade 2 strains and
demonstrate protective efficacy in a murine intratracheal (i.t.) infection model. Inter-
estingly, both MAbs bind to the same glycan epitope as 1C9, but both MAbs can
simultaneously bind to the clade 2 CPS. In summary, we propose that 17H12 and 8F12
could provide life-saving passive immunotherapy and that the glycan epitope could
constitute a potent vaccine target.
RESULTS
Antibody generation with clade 1 and 2 PA-conjugated CPS immunization.
Standard immunization protocols with a combination of protective antigen (PA)-
conjugated CPS derived from clade 1 (strain 36) and 2 (strain 34) K. pneumoniae strains
in complete Freund’s adjuvant yielded 10 different MAb-excreting hybridoma clones
that bound either clade 1 or 2 CPS with high affinity. Two clones that were high
producers (15 to 20 g/ml) of anti-clade 2 MAbs were selected for further character-
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ization (Table 1). Sequence analysis showed that the variable regions of MAbs 17H12
and 8F12 differed by only three amino acids, two of which are in complementarity-
determining region 2 (CDR2), of the heavy chain V (VH) region. The VH sequences of
8F12 and 17H12 are 98.96 and 98.61% (five and four mutated residues, respectively)
identical to the IGHV5-12*02 germ line family. The MAbs have identical light chain V (VL)
sequences, which are 98.98% (three mutations) identical to the IGKV1-135*01 germ line
family. Binding affinity for purified polysaccharide was evaluated by enzyme-linked
immunosorbent assay (ELISA). Both MAbs have affinities in the nanomolar range.
Specifically, Kd binding to clade 2 CPS for 8F12 was 23.2  2.4 nM and that for 17H12
was 13.2  4.4 nM. In addition, 17H12 IgG3 was found to bind to clade 1 CPS with a
Kd of 490  59 nM.
Both 17H12 and 8F12 bind to the hexasaccharide epitope recognized by 1C9.
First, the specificity of MAb 17H12 and 8F12 binding to CPS was tested by agglutination
assays (Table 2), which demonstrated that 8F12 agglutinated 25 (96.2%) of 26 clade 2
strains and 17H12 agglutinated all 26 (100%). Next, the cross-agglutination of strains of
noncognate clade 1 CPS by these MAbs was explored. 17H12 agglutinated all 16 (100%)
clade 1 strains, whereas 8F12 bound to 8 (50%) of the clade 1 strains. In addition, we
found that 17H12 agglutinated 11 other (non-ST258-associated) K. pneumoniae sero-
types, including K1, K2, K3, K16, K24, K27, K35, K38, K39, K43, and K63 (data not shown).
Next, binding was studied with recently published glycan arrays that identified a
hexasaccharide epitope that is bound by 1C9, a previously described IgM that binds
clade 2 CPS (Fig. 1A) (19). 1C9 was found to agglutinate fewer strains than 17H12 and
8F12, with no agglutination of clade 1 strains. We first tested if 1C9 IgM or monomeric
1C9 bind to CPS simultaneously with 17H12 or 8F12 by standard competition ELISA
using fluorescently labeled 8F12 and 17H12 MAbs (Fig. 1B and C). Inhibition observed
at higher concentrations in these assays could be the result of steric hindrance and/or
overlapping epitopes only (20). Interestingly, 17H12 binding increased 8F12 binding to
CPS, whereas 8F12 binding did not affect 17H12 binding. Next, we tested if 17H12 and
8F12 bind to previously described synthetic glycans, as well as the native CPS of K.
pneumoniae strains and control CPS (Fig. 1A). Our data show that 17H12 binds to
hexasaccharide 1, which was originally designed on the basis of the repeat glycan
structures of the CPS isolated from the clade 2 NIH outbreak strain. Glycans 5 and 5=,
which constitute shorter synthetic glycans of the same clade 2 CPS, are also recognized
by this MAb. In contrast, 8F12 binds only hexasaccharide 1 and none of the shorter
synthetic glycans. Instead, this MAb recognizes the K1 CPS and demonstrates weak
binding to the CPS of a wzi-50 mutant strain (clade1) and a K2 strain. These results
further support the above findings, suggesting that the epitopes bound by 17H12 and
8F12 are not identical, although their variable regions differ by only two amino acids.
In addition, these binding studies underscore the importance of hexasaccharide 1 as a
potential vaccine target to prevent clade 2 infections.
17H12 and 8F12 decrease biofilm formation and serum resistance and increase
complement binding. The formation of CR K. pneumoniae strain 39 biofilms on
TABLE 1 Identification of germ line variable region genes for CR CPS-specific MAbs
MAb
Isotype/clade
immunization VH gene VH family JH gene D gene VL family VL gene JL gene
8F12 IgG3/clade 2 AF305910 IGHV1-84*02 IGHJ2*01 IGHD1-3*01 AJ235936 IGKV16-104*01 IGKJ5*01
17H12 IgG3/clade 2 AF305910 IGHV1-84*02 IGHJ2*01 IGHD1-3*01 AJ235936 IGKV16-104*01 IGKJ5*01
TABLE 2 Agglutination of CR K. pneumoniae clinical isolates by MAbs
Clade
No. of isolates agglutinated/total (%)
8F12 17H12
1 8/16 (50.0) 16/16 (100)
2 25/26 (96.2) 26/26 (100)
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polystyrene plates was measured after 16 h of growth in the presence or absence of
MAbs. 8F12 significantly decreased biofilm formation with respect to IgG control even
at concentrations as low as 0.156 mg/ml (P  0.01) (Fig. 2A). A similar, albeit less
pronounced, effect was observed with 17H12, whereas the IgG isotype control MAb
had no effect in these assays. The polysaccharide capsule also shields K. pneumoniae
from the bactericidal effect of serum, which enables it to grow in blood (3). Our data
show that coincubation of CR K. pneumoniae strain 39 with either 8F12 or 17H12
significantly impairs the ability of the strain to replicate in 75% normal human serum
(Fig. 2B). Consistent with that observation, both MAbs increased C3c complement
deposition on CR K. pneumoniae strain 39 (Fig. 2C, P  0.001). Furthermore, the
deposition of the membrane attack complex (MAC) was also found to be significantly
increased (Fig. 2D, P  0.01 for 8F12 and P  0.001 for 17H12). Neither the deposition
of C3c complement nor the deposition of MAC components was found to be increased
when CR K. pneumoniae was coincubated with an IgG control antibody.
Antibodies promote intra- and extracellular killing of CR K. pneumoniae. Op-
sonophagocytic killing assays can predict the protective efficacy of anticapsular MAbs.
Therefore, the phagocytosis of clade 2 CR K. pneumoniae strains by primary human
neutrophils was evaluated. Clade 2 CR K. pneumoniae strain 39 was poorly phagocy-
tosed by neutrophils in the presence of phosphate-buffered saline (PBS) or IgG control
antibody, whereas coincubation with 8F12 or 17H12 significantly increased the phago-
cytosis of CR K. pneumoniae strain 39 even in the absence of active normal human
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FIG 1 MAb binding characterization. (A) Glycan array printing schema and MAb binding. 8F12 and 17H12 bind to hexasaccharide 268
and clade 2 CPS. BSA, bovine serum albumin as negative control; and positive MAb is the previously reported 1C9 (18, 19). (B) MAbs
17H12, 1C9 (IgM), and monomeric 1C9 compete with fluorescently labeled 8F12 for binding to K. pneumoniae strain 34 CPS at higher
concentrations. 17H12 increases 8F12 binding at 8F12-to-17H12 ratios of 1:0.4 to 1:7. (C) 8F12 and 1C9 compete with 17H12 for CPS
binding at higher concentrations.
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serum (P  0.05 and P  0.0001, respectively, Fig. 3A). Killing was also significantly
enhanced by 8F12 and even more efficiently by 17H12 (P  0.05 and P  0.0001,
respectively, Fig. 3D). Again, these effects were found to be dependent on a CR K.
pneumoniae-specific antibody. Most importantly, the opsonophagocytic killing efficacy
of 17H12 was confirmed in 19 other clinical clade 2 CR K. pneumoniae strains (Fig. S1),
emphasizing the potential therapeutic use of anticapsular antibodies despite CPS
variability.
Reactive oxygen species (ROS) production is important for neutrophil-mediated
killing and was examined in the presence of MAbs. CR K. pneumoniae clade 2 strain 39
cocultured with neutrophils poorly induced ROS production alone, but its induction of
ROS significantly increased in the presence of 8F12 or 17H12 (area-under-the-curve
analysis, P  0.05 and P  0.01, respectively, Fig. 3C). NETosis is a mechanism by which
neutrophils excrete neutrophil extracellular traps (NETs) that trap bacteria and promote
extracellular killing by minimizing damage to host cells. This mechanism of extracellular
killing can be enhanced by MAbs (8). We evaluated the mobilization of neutrophil
elastase (NE) to the nucleus, an established NETosis marker (21). We found that both
8F12 and 17H12 promoted the colocalization of NE in the nucleus, whereas PBS or IgG
control treatment (Fig. 3D) had no effect.
17H12 and 8F12 promote in vivo protection in a murine i.t. infection model.
Although clade 2 strains constitute the more virulent CR K. pneumoniae clade in human
infection, murine infection usually does not result in death unless very large inocula are












































































































































FIG 2 In vitro protection of MAbs against clade 2 CR K. pneumoniae. (A) 8F12 and 17H12 reduce biofilm formation when incorporated
in cultures of CR K. pneumoniae strain 39. Log-transformed values were compared with respect to IgG control. (B) 8F12 and 17H12 prevent
the replication of CR K. pneumoniae strain 39 in the presence of NHS. Survival ratio expresses the amount of growth with respect to initial
inoculum. Survival ratio of 1 means inability to replicate, whereas survival ratios 1 expresses moderate growth in serum. PBS
comparison was done with two-way ANOVA with Dunnett’s multiple comparison correction. (C) C3c complement deposition onto CR K.
pneumoniae strain 39 cells is promoted in the presence of 8F12 and 17H12. (D) MAC deposition onto CR K. pneumoniae strain 39 cells is
promoted by 8F12 and 17H12. Log-transformed values from C and D were compared with the IgG control. All experiments were carried
out independently in triplicate. P values were determined by one-way ANOVA with multiple-comparison correction. *, P  0.05; **, P 
0.01; ***, P  0.001; ****, P  0.0001.
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quantifying tissue bacterial burdens in a pulmonary infection model. These experi-
ments document a significant decrease in organ CR K. pneumoniae strain 39 burdens
when mice were coinjected with 17H12 or 8F12, whereas no effect on the organ






























































































































FIG 3 Clade 2 MAbs promote neutrophil phagocytosis and killing of clade 2 CR K. pneumoniae. (A) Neutrophil phagocytosis of CR
K. pneumoniae strain 39 cells was increased 2 and 3 h after incubation with 8F12 and 17H12 as detected by pHrodo signaling. (B)
Increased neutrophil killing of CR K. pneumoniae strain 39 cells in the presence of 8F12 and 17H12. (C) Incubation with specific MAbs
increased ROS production. (D) MAbs increased NETosis production. Black asterisks mean comparison with respect to PBS, whereas
red asterisks mean comparison with respect to IgG control. P values were determined by one- or two-way ANOVA with



























































































FIG 4 17H12 promotes in vivo protection in an i.t. murine infection model. (A) Organ bacterial burdens were decreased in the lungs,
liver, and spleen after 17H12 or 8F12 treatment. (B) The lung cytokine IL-6 level was significantly reduced. P values were determined
by two-way ANOVA with multiple-comparison correction. *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001. Black asterisks
denote P values compared to PBS, and blue asterisks denote P values compared to an isotype IgG control.
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mice. In the liver and spleen, bacterial counts were found to be under the limit of
detection in MAb-treated mice, either because dissemination to the specific organ was
prevented or because clearance of the organ was promoted. Consistent with the
observed protective efficacy, in vivo cytokine analysis of infected tissue also demon-
strated differences (Fig. 4B). Most notably, levels of the proinflammatory mediator
interleukin-6 (IL-6), which enhances neutrophil-mediated killing, was significantly re-
duced in the presence of both 8F12 and 17H12 and levels of granulocyte-macrophage
colony-stimulating factor, gamma interferon, IL-1, and IL-18 were also decreased.
Histological analysis of lung sections confirmed less recruitment of inflammatory cells
in MAb-treated mice than in controls (data not shown).
DISCUSSION
CR K. pneumoniae strains continue to be the leading multidrug-resistant members of
the family Enterobacteriaceae, and specifically infections with clade 2 ST258 CR K.
pneumoniae strains are associated with poor clinical outcomes (1, 5). Given the limited
new antibiotic treatments in development, new therapies and preventive measures are
crucial to limit the health care burden these infections cause. Ample animal data have
demonstrated protective efficacy of vaccines and MAbs targeting the polysaccharide
capsule of various microbes (22–24). Vaccination with protective epitopes of CR K.
pneumoniae CPS could prevent infections and colonization in individuals in high-risk
settings such as long-term hospitalization or nursing home residency. Meanwhile,
MAbs could be used to treat patients who cannot develop an effective immune
response. Though our MAbs might treat only infections by clade 2 CR K. pneumoniae
strains, the Prevnar 7 antipneumococcal conjugate vaccine is protective, despite cov-
ering only 50% of the serotypes prevalent in some countries (25, 26). Also, protection
against 50% of the CR K. pneumoniae strains in the United States and 80% of those in
other countries could have a notable impact on the outcome of these infections
because they are more likely to lead to death (1).
Our data indicate that 8F12 and 17H12 recognize similar antigen structures of the
clade 2 CPS, as both bind to hexasaccharide 1, the epitope that 1C9 also recognizes
(19). However, certain differences were found. Specifically, only 17H12 is able to bind
to the smaller oligosaccharides, whereas neither 8F12 nor 1C9 is (this work and
reference 19). Interestingly, the 8F12 and 17H12 sequences differ by only two amino
acids in VH CDR2 (56Gly 57Ser and 56Ser 57Asn, respectively). Single amino acid
changes in CDR2 have been sufficient to increase MAb epitope binding elsewhere (27)
and could facilitate 17H12 binding to smaller oligosaccharides. Interestingly, biofilm
formation was inhibited more in the presence of 8F12 than in the presence of 17H12,
further supporting the notion that the interactions of the MAbs with the CPS differ. Also
of note is the enhancement of 8F12 binding to CR K. pneumoniae CPS upon binding by
17H12, which could indicate cooperative antigen binding (28). Such cooperativity is
responsible for transforming nonneutralizing ebolavirus antibodies into potent neu-
tralizers (29) and also for synergistic effects observed when MAbs are combined for
treatment (30), which could also be considered for 17H12 and 8F12. Although it is still
unclear, it is possible that binding of 17H12 exposes an epitope that can now better
interact with the variable region of 8F12. Alternatively, such binding cooperativity has
also been proposed to occur through non-covalent Fc-Fc intermolecular interactions
between two mouse IgG3 antibodies (43). Crystallographic investigations could be
employed to test these hypotheses.
ST258 strains have been shown to have high resistance to complement-mediated
killing and phagocytosis by neutrophils (3, 31, 32). Both 17H12 and 8F12 efficiently
promote the deposition of complement and MAC and, as a result, reduce resistance to
human serum. In addition, neutrophil phagocytosis is significantly increased and
induces ROS and effective killing by neutrophils. It also increases extracellular killing by
NETosis, another mechanism to facilitate the clearance of K. pneumoniae infections (33).
This effect has been pointed out as a potential therapeutic approach to the treatment
of CR K. pneumoniae infections (32).
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The lack of good in vivo animal models that mimic the natural pathogenesis of CR
K. pneumoniae infections, which are characterized by a prolonged smoldering course
and occasionally even sustained bacteremia (34), impedes the development of alter-
native therapeutic modalities that do not target lipopolysaccharide. Even clade 2 CR K.
pneumoniae strains are not very virulent in murine models unless large inocula (108
bacteria) are used, and in these cases, mice typically die of septic shock in 48 h (3, 18,
31, 35). In our experience, even a 0.5-log reduction of bacterial inocula prevents mouse
lethality (data not shown). Furthermore, this time course and modality of death do not
align with the median time to death seen in CR K. pneumoniae-infected patients, which
is more than a week after evidence of bacteremia (1). Similar to studies with Mycobac-
terium tuberculosis (36), protective efficacy of MAbs was demonstrated when preincu-
bated CR K. pneumoniae inocula were injected i.t. Both MAbs were able to decrease
lung, liver, and spleen bacterial burdens effectively, and they reduce proinflammatory
cytokines. Organ bacterial burden reduction and cytokine analysis are normally used as
indications of MAb efficacy (8, 11, 37, 38). The dual activity of IL-6, a pro- and
anti-inflammatory cytokine, has been found to be associated with severity of disease
and systemic inflammatory responses in infections by other pathogens such as influ-
enza virus and Streptococcus pneumoniae. There, protection by MAb has been shown to
decrease IL-6 levels and improve survival (38, 39).
In summary, these two MAbs can be considered candidates for an antibody-based
approach to the treatment of CR K. pneumoniae-infected patients otherwise with
limited therapeutic options. Furthermore, glycan array binding studies highlight the
importance of previously described hexasaccharide 1, which constitutes a relevant
epitope on all of the clade 2 strains tested. This oligosaccharide should be further
explored for vaccine development.
MATERIALS AND METHODS
CR K. pneumoniae strains. CR K. pneumoniae strains were collected from patients at the Montefiore
Medical Center (MMC) and the Stony Brook University (SBU) hospital under institutional review board
(IRB)-approved protocols. Clade 2 MMC K. pneumoniae strains 34, 39, M1, M5, M6, M25, M26, M48, M49,
M47, and M13 and clade 1 MMC K. pneumoniae strain 36 have been described previously (18). Clade 2
SBU strains 4, 12, 20, 32, 34, 35, 36, 45, 86, and 208 were isolated at the SBU hospital. K. pneumoniae
strains were cultured in Luria-Bertani (LB) broth or agar at 37°C.
CPS purification and conjugation. CPS was isolated and conjugated to Bacillus anthracis PA by the
1-cyano-4-dimethylaminopyridinium tetrafluoroborate method as previously described (8).
MAb production. MAbs to ST258 CPS were generated by immunizing 6- to 8-week-old BALB/c mice
with 100 g of PA-conjugated CPS of K. pneumoniae strains 36 and 34 in complete Freund’s adjuvant,
followed by boosters of PA-conjugated CPS in incomplete Freund’s adjuvant 2, 4, and 6 weeks later.
Fusion and cloning were performed as previously described (8). The 8F12 and 17H12 variable regions
were sequenced by GenScript and analyzed with the International ImMunoGeneTics Information System
software program. The affinities of the MAbs were calculated by ELISA as previously described (8).
Labelling of MAbs with DyLight 549 (ThermoFisher Scientific) was done following manufacturer’s
protocol. Reduction of the multimeric form of IgM 1C9 MAb was done with 0.15 M of -mercaptoethanol
in TBS (1:1 v/v) for 1 h at 37°C as previously reported (44). Either commercial murine IgG3 (Crown
Biosciences Inc.), which recognizes hen egg lysozyme, or 9D8, an IgG3 MAb that binds to arabinomannan
(36), was used as an IgG control antibody.
Agglutination assays. Agglutination assays were carried out as previously described (40).
Glycan arrays. Development of glycan arrays and their use in binding assays are described
elsewhere (19).
Biofilm production assays. Biofilm production assays were carried out as previously described after
16 h of growth (18).
Complement deposition assays. Testing for C3c complement deposition was performed as previ-
ously described (8). Assays querying MAC deposition were performed similarly but with 1 h of incubation
of normal human serum (NHS) plus bacteria with or without MAbs. MAC was detected with an Alexa
Fluor 647-conjugated anti-human C5b-9 (Bioss Antibodies) with 20 min of incubation at 4°C. Flow
cytometry was used to quantify the complement deposition signal. Quantification was performed by
multiplying the percentage of bacteria moving into the gate by the average fluorescence of a defined
population (X-mean), to give a fluorescence index. Results of both assays are expressed by the increment
of fluorescein isothiocyanate or Alexa Fluor 647 signal with respect to PBS incubation.
Human serum resistance assays. Human serum resistance assays were performed as previously
described (8).
NETosis. NETosis was carried out as previously described (41). Colocalization of NE was quantitated
with ImageJ. Ten different cells were analyzed per condition.
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Phagocytosis experiments. J744.16 murine macrophages and human primary neutrophils were
used for phagocytosis assays with bacteria labeled with pHrodo (Life Technologies, Inc.) as previously
described (8). Neutrophils were purified as previously described (8). Neutrophil phagocytosis was carried
out at a MOI of 0.1. Cells (1  106/well) were seeded and 105 CR K. pneumoniae cells incubated for 1 h
with PBS, and IgG control or 17H12 were added to the wells. After 1 h, extracellular bacteria were washed
out with fresh media twice and incubated for 30 min with 100 g/ml of polymyxin B. Then, polymyxin
B was washed out with fresh media twice and macrophage cells were lysed with H2O. Bacteria were
plated in LB plates in triplicates with the appropriate dilutions. Neutrophil killing was assayed at a
multiplicity of infection (MOI) of 0.1 as previously described (41). In vitro murine J744.16 cell line
phagocytosis was assayed by plating 5  105 cells/well. After overnight culture, 106 cells of different CR
K. pneumoniae strains were incubated for 1 h with PBS, IgG control, or 17H12 and added to the wells at
an MOI of 1:1. After 30 min of incubation, extracellular bacteria were washed out with fresh medium
twice and incubated for 30 min with 100 g/ml polymyxin B. The polymyxin B was then washed out with
fresh medium twice and macrophages were lysed with H2O. Bacteria were plated on LB plates in triplicate
with the appropriate dilutions.
Neutrophil ROS production. ROS production was assayed with luminol as previously described,
with modifications (42). Briefly, 5  105 neutrophils in RPMI medium plus 10% fetal bovine serum were
plated on a 96-well luminometer plate (Nunc, Roskilde, Denmark). A total of 5  106 CFU of CR K.
pneumoniae previously incubated for 1 h with 40 g/ml PBS, IgG control, or specific MAbs were added
with luminol. Immediately after stimulus addition, 50 l of RPMI medium containing 200 M luminol was
distributed into each well. ROS production was determined by measuring luminescence every 2 min for
2 h at 37°C in a microplate reader (Molecular Devices). Data are expressed as relative luciferase units or
total relative luciferase units under the curve in 90 min. Statistical significance of differences was
calculated by one-way analysis of variance (ANOVA) from data of three independent experiments.
I.t. infection model. Female BALB/c mice 6 to 8 weeks old were used. CR K. pneumoniae strain 39
(2  108 CFU/ml) was incubated with 17H12, IgG control, or PBS at 5 mg/ml for 1 h. A 50-l volume with
107 CFU preincubated with 250 g of MAbs was then injected i.t. After 24 h, mice were euthanized and
the livers, spleens, and lungs of eight mice were processed for enumeration of bacteria in homogenized
tissue, histology observation, and cytokine analysis.
Statistical analysis. Statistical tests were performed with GraphPad Prism 6 for Mac. Data for biofilm,
complement deposition, netosis, and neutrophil phagocytosis were log-transformed and tested for
normality and equality of variance and were deemed to be parametric. For multigroup comparisons of
parametric data (e.g., phagocytosis, log-transformed CFU counts, log-transformed complement deposi-
tion), ANOVA and post hoc analysis with Tukey’s, Šidák’s, or Dunnett’s comparison test were used. Data
in figures are deposited as raw data, not log-transformed.
Ethics statement. Animal study protocols were approved by the Animal Committee (IACUC) at SBU
(approval no. 628253). This study is in strict accordance with federal, state, local, and institutional
guidelines that include the Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act,
and Public Health Service Policy on Human Care and Use of Laboratory Animals. All surgery was
performed under ketamine-and-xylazine anesthesia, and every effort was made to minimize suffering.
Human studies were approved by the SBU Human Subjects Committee (IRB approval no. 718744).
Healthy donors gave written informed consent for blood donation.
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Erratum for Diago-Navarro et al., “Novel, Broadly Reactive
Anticapsular Antibodies against Carbapenem-Resistant
Klebsiella pneumoniae Protect from Infection”
Elizabeth Diago-Navarro,a Michael P. Motley,a,b Gonzalo Ruiz-Peréz,c Winnie Yu,a Julianne Austin,a Bruna M. S. Seco,d
Guozhi Xiao,d Aniska Chikhalya,b Peter H. Seeberger,d Bettina C. Friesa,b
aDepartment of Medicine, Infectious Disease Division, Stony Brook University, Stony Brook, New York, USA
bDepartment of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, USA
cUniversidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain
dDepartment of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany
Volume 9, issue 2, e00091-18, 2018, https://doi.org/10.1128/mBio.00091-18. After
careful review of the legend of Fig. 3, we realized that there was an error in the section
describing panel A. The revised legend for Fig. 3A should read “Neutrophil phagocytosis
of CR K. pneumoniae strain 39 cells was increased after incubation with 8F12 and 17H12
in the presence of NHS or HI-NHS.” We also noticed that on PDF page 5 (first
paragraph), the statement about neutrophil killing should reference Fig. 3B, not Fig. 3D.
Published 12 June 2018
Citation Diago-Navarro E, Motley MP, Ruiz-
Peréz G, Yu W, Austin J, Seco BMS, Xiao G,
Chikhalya A, Seeberger PH, Fries BC. 2018.
Erratum for Diago-Navarro et al., “Novel,
broadly reactive anticapsular antibodies
against carbapenem-resistant Klebsiella
pneumoniae protect from infection.” mBio
9:e01005-18. https://doi.org/10.1128/mBio
.01005-18.
Copyright © 2018 Diago-Navarro et al. This is
an open-access article distributed under the
terms of the Creative Commons Attribution 4.0
International license.




May/June 2018 Volume 9 Issue 3 e01005-18 ® mbio.asm.org 1
